Click here to read the notification from Pfizer relating to the above mentioned product. NSS is effective 1 July 2019.

Price change will be implemented 12 June 2019.

Click here to access the analysis showing the potential to improve profitability by managing to maintain private market.  This analysis takes into account all aspects of the dispensing process and shows these relative to the way in which pharmacy calculates both funded and non-funded items.

ProPharma / PWR have prepared an analysis (based on OP Dispensing) to show what the potential cost per month or stat to the patient would be. This analysis is based on an NSS mark up of 25% for the purpose the analysis only. We cannot and will not advise pharmacy on what mark-up they should apply. That is up to each individual. You can also consider STAT dispensing as those rules do not apply to NSS items.

You must be fully aware of the current market activities and your competitors undertaking to provide NSS prescription items at the lowest price to patients. Patients can now have their prescriptions dispensed from outside their home town. So ensure you do not simply allow this market to grow at your cost.

By making this information available now provides adequate time for pharmacy to discuss the change and the options available to patients.

Providing a choice and letting them make the decision.

Under your existing contract you are required to advise patients of any alternative fully funded options.

As of the date of this notification ProPharma / PWR cannot accept Hysite Eye Drops 0.005% for credit under any circumstances.

We thank you in anticipation of your ongoing support.


About The Author